Bausch + Lomb Validates Intermediate Vision Benefits of enVista Aspire IOLs in Real-World Study
Event summary
- Bausch + Lomb published real-world study results on enVista Aspire and enVista Aspire toric intraocular lenses (IOLs) in Ophthalmology and Therapy journal.
- Study of 84 patients (141 eyes) showed 97.2% of enVista Aspire patients achieved monocular CDVA of 20/25 or better.
- 100% of subjects in both groups achieved binocular UIVA of 20/32 or better with no serious adverse events reported.
- enVista Aspire lenses demonstrated intermediate vision optimization beyond standard monofocal IOLs.
The big picture
This study provides real-world validation for Bausch + Lomb's enVista Aspire platform, which aims to address the growing demand for intermediate vision correction in cataract patients. The results position the company favorably in the competitive IOL market, where differentiation through enhanced visual outcomes is increasingly important. The findings may influence both clinical practice patterns and payer coverage decisions for these advanced lenses.
What we're watching
- Market Differentiation
- Whether Bausch + Lomb can leverage these results to gain market share against competitors offering similar IOL technologies.
- Clinical Adoption
- The pace at which ophthalmologists will incorporate enVista Aspire lenses into standard cataract surgery practices.
- Regulatory Compliance
- How the company will address the noted precautions regarding contrast sensitivity and visual disturbances in future iterations.